Abbott receives expanded FDA approval for HUMIRA
Abbott Laboratories announced today that the U.S. Food and Drug Administration has granted expanded indication to the Company's HUMIRA treatment to include inhibiting progression of structural joint damage and improving physical function in patients with psoriatic arthritis (PsA).
Abbott, which has operations in Worcester, conducted a randomized, placebo-controlled biologic trial in PsA, with patients receiving either HUMIRA 40mg every other week or placebo. More than three times as many patients on placebo experienced joint damage compared to those using HUMIRA at week 24. The trial collected results at weeks 24 and 48.
Patients using Humira also exhibited greater ability to perform physical functions than those on placebo, as qualified by the Health Assessment Questionnaire Disability Index, a scoring system that assesses a patient's ability to perform daily activities.
Abbott specializes in the discovery and development of innovative treatments for immunologic diseases.
WBJ Web Partners
Most Recent
Most Recent
0 Comments